Pulse.

a daily field guide to health research that matters

◆ Console

‹ Sun · 1 Nov 2026
Standard addition

Adjunctive fucoidan, fucoxanthin, and l-carnitine mitigate albuminuria and preserve eGFR over a 12-week treatment period in diabetic kidney disease: A translational study and proof-of-concept randomized clinical trial.

A combination of marine-derived compounds showed promise in slowing kidney disease progression and improving cholesterol in diabetic patients over 12 weeks.

This proof-of-concept randomized clinical trial with preclinical component examined Adjunctive fucoidan, fucoxanthin, and l-carnitine mitigate albuminuria and preserve eGFR over a 12-week treatment period in diabetic kidney disease: A translational study and proof-of-concept randomized clinical trial. FFL also significantly lowered baseline-adjusted LDL (GMR = 0.85; 95% CI: 0.76-0.95; p < 0.01) with a baseline-dependent response maximizing at a 24.28% reduction in patients with baseline dyslipidemia (p < 0.01), while displaying preliminary, exploratory glycemic signals.

What the study was

Study design
Proof-of-concept randomized clinical trial with preclinical component
Category
Treatment Innovation
Maturity
Validated
Journal
Phytomedicine : international journal of phytotherapy and phytopharmacology

Why it surfaced

Abstract-backed proof-of-concept randomized clinical trial with preclinical component relevant to Cardiovascular-metabolic: GLP-1, SGLT2, cardiometabolic risk; scored conservatively because full text was not assessed.

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.